Case report: Infective endocarditis caused by Brevundimonas vesicularis

Login or register to view PDF.
Abstract

Abstract

Background
There are few reports in the literature of invasive infection caused by Brevundimonas vesicularis in patients without immunosuppression or other predisposing factors. The choice of antimicrobial therapy for bacteremia caused by the pathogen requires more case experience to be determined.

Pages

Case presentation
The case of a 40-year-old previously healthy man with subacute endocarditis proposed to be contributed from an occult dental abscess is described. The infection was found to be caused by B. vesicularis on blood culture results. The patient recovered without sequelae after treatment with ceftriaxone followed by subsequent ciprofloxacin therapy owing to an allergic reaction to ceftriaxone and treatment failure with ampicillin/sulbactam.

Conclusion
To our knowledge, this is the first report of B. vesicularis as a cause of infective endocarditis. According to an overview of the literature and our experience, we suggest that third-generation cephalosporins, piperacillin/tazobactam, and ciprofloxacin are effective in treating invasive B. vesicularis infections, while the efficacy of ampicillin-sulbactam needs further evaluation.

Background
Brevundimonas (formerly Pseudomonas) vesicularis is an aerobic nonsporulating and nonfermenting gram-negative bacillus [1] that has been isolated from the external environment [2-5] and human clinical specimens [6-15]. There have been only eight descriptions of infections in human beings caused by the microorganism, with only four cases of bacteremia reported in the literature [Table 1, [8-15]]. Five cases of B. vesicularis infection were attributed to community sources [10,12-15] and three to nosocomial sources [8,9,11]. Such underlying diseases as autoimmune disorders associated with long-term steroid use, end-stage renal disease treated by hemodialysis, and sickle cell anemia with functional asplenia contributed to B. vesicularis infections in 6 of the 8 reported cases due to the patients' immunocompromised state [Table 1, [8-12,15]]. B. vesicularis infection has therefore been classified as opportunistic [8-12,15]. We report here a case of infective endocarditis caused by B. vesicularis in a patient without comorbid disease. The low number of cases reported of B. vesicularis infection in humans limits the body of knowledge on the spectrum of disease caused by this pathogen as well as optimal treatment regimens. The treatment course of the current case and previous cases of B. vesicularis infection is further discussed.

Table 1. Summary of reported cases of Brevundimonas vesicularis infection in humans

Pages

References
  1. Gilligan PH, Lum G, Vandamme PAR, Whittier S: Burkholderia, Stenotrophomonas, Ralstonia, Brevundimonas, Comamonas, Delftia, Pandoraea and Acidovorax. In Manual of Clinical Microbiology. 8th edition. Edited by: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH. Washington: American Society of Microbiology; 2003:729-748.
  2. Davis EP, Boopathy R, Manning J: Use of trinitrobenzene as a nitrogen source by Pseudomonas vesicularis isolated from soil. Curr Microbiol 1997, 34:192-197.
  3. Morais PV, da Costa MS: Alterations in the major heterotrophic bacterial populations isolated from a still bottled mineral water. J Appl Bacteriol 1990, 69:750-757.
  4. Koide M, Miyata T, Nukina M, Teramoto T, Nakanishi H, Kamiki T, Umeda B, Nakai H: A strain of Pseudomonas vesicularis isolated from shower hose which supports the multiplication of Legionella. Kansenshogaku Zasshi 1989, 63:1160-1164.
  5. Aspinall ST, Graham R: Two sources of contamination of a hydrotherapy pool by environmental organisms. J Hosp Infect 1989, 14:285-292.
  6. Otto LA, Deboo BS, Capers EL, Pickett MJ: Pseudomonas vesicularis from cervical specimens. J Clin Microbiol 1978, 7:341-345.
  7. Segers P, Vancanneyt M, Pot B, Torck U, Hoste B, Dewettinck D, Falsen E, Kersters K, De Vos P: Classification of Pseudomonas diminuta Leifson and Hugh 1954 and Pseudomonas vesicularis B─é─¢sing, D─é┬Âll, and Freytag 1953 in Brevundimonas gen. nov. as Brevundimonas diminuta comb. nov. and Brevundimonas vesicularis comb. nov., respectively. Int J Syst Bacteriol 1994, 44:499-510
  8. Planes AM, Ramirez A, Fernandez F, Capdevila JA, Tolosa C: Pseudomonas vesicularis bacteraemia. Infection 1992, 20:367-368.
  9. Gilad J, Borer A, Peled N, Riesenberg K, Tager S, Appelbaum A, Schlaffer F: Hospital-acquired Brevundimonas vesicularis septicaemia following open-heart surgery: case report and literature review. Scand J Infect Dis 2000, 32:90-91.
  10. Oberhelman RA, Humbert JR, Santorelli FW: Pseudomonas vesicularis causing bacteremia in a child with sickle cell anemia. South Med J 1994, 87:821-822.
  11. Vanholder R, Vanhaecke E, Ringoir S: Pseudomonas septicemia due to deficient disinfectant mixing during reuse. Int J Artif Organs 1992, 15:19-24.
  12. Calegari L, Gezuele EG, Torres E, Carmona C: Botryomycosis caused by Pseudomonas vesicularis. Int J Dermatol 1996, 35:817-818.
  13. Chi CY, Fung CP, Wong WW, Liu CY: Brevundimonas bacteremia: two case reports and literature review. Scan J Infect Dis 2004, 36:59-61.
  14. Sofer Y, Zmira S, Amir J: Brevundimonas vesicularis septic arthritis in an immunocompetent child. Eur J Pediatr 2007, 166:77-78.
  15. Choi W, Lee C, Kim A, Choi JW, Seo S, Lee J, Pyo H, Kwon YJ: CAPD peritonitis due to Brevundimonas vesicularis. Perit Dial Int 2006, 26:510-512.
  16. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disc susceptibility tests. Approved standard, M2-A9, 9th edition. National Committee for Clinical Laboratory Standards, Wayne Pa 2006.
  17. Clark WA, Hollis DC, Weaver RE, (Eds): Identification of unusual pathologic gram-negative aerobic and facultatively anaerobic bacteria. Department of Health and Human Services, Centers for Disease Control, Atlanta, US 1984, 286-287.
  18. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005, 111:e394-e434.